# Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

> **NCT02140255** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1120 (estimated)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- **DRUG:** Nevirapine (NVP)
- **DRUG:** Lopinavir/Ritonavir (LPV/r)
- **DRUG:** Raltegravir (RAL)
- **DRUG:** VRC01
- **DRUG:** Dolutegravir (DTG)
- **DRUG:** VRC07-523LS

## Key facts

- **NCT ID:** NCT02140255
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-01-23
- **Primary completion:** 2028-01-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 1120 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140255, "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02140255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*